colorectal carcinoma
colorectal carcinoma
Explore linked clinical trials. Standard reference: MONDO:002433124 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, adenoma, benign urinary system neoplasm, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, cancer, carcinoma, colonic disorder, colorectal cancer, colorectal carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, intestinal disorder, kidney cancer, kidney disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant mesothelioma, malignant pancreatic neoplasm, mesothelial neoplasm, mesothelioma, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian carcinoma, ovarian disorder, pancreas disorder, pancreatic neoplasm, pleural neoplasm, rectal disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, triple-negative breast carcinoma, urinary system disorder | Recruiting | Not stated | 2026-09-25 | NCT04981119 | |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Cancer of Gastrointestinal Tract, Carcinoma, Ductal, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, adenocarcinoma, carcinoma, colonic disorder, colorectal cancer, colorectal carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, intestinal disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic ductal adenocarcinoma, pancreatic neoplasm, rectal disorder | Recruiting | Phase 1 / Phase 2 | 2026-09-22 | NCT06445062 | |
| Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, intestinal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, non-small cell lung carcinoma, pancreas disorder, pancreatic adenocarcinoma, pancreatic neoplasm, rectal disorder, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 | 2026-09-17 | NCT07349537 | |
| First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, carcinoma, colorectal carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, non-small cell lung carcinoma, skin disorder, squamous cell carcinoma, triple-negative breast carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-09-11 | NCT06657222 | |
| Colon Health Champion Program | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Not yet recruiting | Not applicable | 2026-09-01 | NCT07796334 | |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal cancer, colorectal carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, malignant colon neoplasm, neoplasm, rectal disorder | Recruiting | Phase 1 | 2026-08-26 | NCT07321106 | |
| Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 2 | 2026-08-18 | NCT06728072 | |
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. | Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, colonic disorder, colorectal carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, intestinal disorder, kidney cancer, kidney disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, rectal disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, urinary system disorder | Not yet recruiting | Not applicable | 2026-08-04 | NCT07689812 | |
| Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, rectal disorder, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-08-03 | NCT07397338 | |
| Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Phase 2 | 2026-06-16 | NCT06106308 | |
| A Study of a Urine Test to Detect Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Hemorrhage, Hemorrhage, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colonic disorder, colorectal cancer, colorectal carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Not stated | 2026-06-15 | NCT07649057 | |
| A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenoma, bronchial neoplasm, bronchogenic carcinoma, cancer, colonic disorder, colonic neoplasm, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, intestinal disorder, lung cancer, lung disorder, lung neoplasm, malignant colon neoplasm, malignant endocrine neoplasm, malignant mesothelioma, malignant pancreatic neoplasm, mesothelial neoplasm, mesothelioma, neoplasm, non-small cell lung carcinoma, non-small cell squamous lung carcinoma, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, pleural neoplasm, rectal cancer, rectal disorder, rectal neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-06-12 | NCT06051695 | |
| Noninvasive Early Diagnosis of Colorectal Cancer Using Odor-Targeted Capture, Point-of-Care Testing, and Intelligent Analysis | colorectal carcinoma, neoplasm, precancerous condition | Not yet recruiting | Not stated | 2026-06-02 | NCT07620743 | |
| A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. | colorectal carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-05-01 | NCT07283367 | |
| Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM | colorectal carcinoma | Not yet recruiting | Phase 2 | 2026-04-28 | NCT07381309 | |
| The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer | colorectal carcinoma | Recruiting | Phase 1 / Phase 2 | 2025-10-02 | NCT07204574 | |
| A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression | Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, cancer, carcinoma, colonic disorder, colonic neoplasm, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, head and neck squamous cell carcinoma, intestinal disorder, kidney cancer, kidney disorder, lung cancer, lung disorder, lung neoplasm, malignant colon neoplasm, neoplasm, non-small cell lung carcinoma, rectal cancer, rectal disorder, rectal neoplasm, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, squamous cell carcinoma, triple-negative breast carcinoma, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2025-09-09 | NCT06682793 | |
| HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, colorectal carcinoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 1 | 2025-04-27 | NCT05167071 | |
| A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression | Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, cancer, colonic disorder, colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, intestinal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, non-small cell lung carcinoma, non-small cell squamous lung carcinoma, pancreas disorder, pancreatic neoplasm, rectal disorder, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2025-04-25 | NCT05736731 | |
| Study to Evaluate D-1553 in Subjects With Solid Tumors | colorectal carcinoma, non-small cell lung carcinoma | Active, not recruiting | Phase 1 / Phase 2 | 2025-03-18 | NCT04585035 | |
| A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, colorectal carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 1 | 2024-09-24 | NCT06259552 | |
| Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colorectal carcinoma, metastatic malignant neoplasm, neoplasm | Not yet recruiting | Phase 2 | 2024-09-19 | NCT06593548 | |
| Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Not yet recruiting | Phase 1 / Phase 2 | 2024-01-08 | NCT06195670 | |
| Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC | colorectal carcinoma | Not yet recruiting | Phase 2 | 2022-05-03 | NCT05239650 |